Mechanism and adverse effects of COVID-19 drugs : a basic review
IJPPP Copyright © 2021..
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is chronic, inflammatory. Although the exact mechanisms of COVID-19 have not been yet discovered some drugs are found helpful for its treatment. These drugs which are divided into some lines therapies, have demonstrated to be helpful for COVID-19 patients based on immune basic and its antiviral properties of the disease. Previous studies have been indicated that deterioration of COVID-19 condition is associated with a weaker immune system. Most of these therapies impact on the immune system and immune cells. Beside many beneficial effects of these drugs, some adverse effects (AE) have been reported in many experiments and clinical trials among patients suffering from COVID-19. In this review, we conclude some AEs of vitamin-D, zinc, remdesivir, hydroxychloroquine or chloroquine, azithromycin, dexamethasone, amantadine, aspirin reported in different papers and we continue the rest of the drugs in second part of our review article.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
International journal of physiology, pathophysiology and pharmacology - 13(2021), 4 vom: 26., Seite 102-109 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohammad Zadeh, Nadia [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.09.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM33082029X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33082029X | ||
| 003 | DE-627 | ||
| 005 | 20231225212116.0 | ||
| 007 | tu | ||
| 008 | 231225s2021 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1102.xml |
| 035 | |a (DE-627)NLM33082029X | ||
| 035 | |a (NLM)34540130 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohammad Zadeh, Nadia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanism and adverse effects of COVID-19 drugs |b a basic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 21.09.2021 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a IJPPP Copyright © 2021. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) is chronic, inflammatory. Although the exact mechanisms of COVID-19 have not been yet discovered some drugs are found helpful for its treatment. These drugs which are divided into some lines therapies, have demonstrated to be helpful for COVID-19 patients based on immune basic and its antiviral properties of the disease. Previous studies have been indicated that deterioration of COVID-19 condition is associated with a weaker immune system. Most of these therapies impact on the immune system and immune cells. Beside many beneficial effects of these drugs, some adverse effects (AE) have been reported in many experiments and clinical trials among patients suffering from COVID-19. In this review, we conclude some AEs of vitamin-D, zinc, remdesivir, hydroxychloroquine or chloroquine, azithromycin, dexamethasone, amantadine, aspirin reported in different papers and we continue the rest of the drugs in second part of our review article | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Mechanism | |
| 650 | 4 | |a adverse effect | |
| 650 | 4 | |a drugs | |
| 700 | 1 | |a Mashinchi Asl, Nazli Sadat |e verfasserin |4 aut | |
| 700 | 1 | |a Forouharnejad, Khatereh |e verfasserin |4 aut | |
| 700 | 1 | |a Ghadimi, Keyvan |e verfasserin |4 aut | |
| 700 | 1 | |a Parsa, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Omidi, Ashkan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of physiology, pathophysiology and pharmacology |d 2009 |g 13(2021), 4 vom: 26., Seite 102-109 |w (DE-627)NLM197528686 |x 1944-8171 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:4 |g day:26 |g pages:102-109 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 4 |b 26 |h 102-109 | ||